Sponsors
Moderna’s mRNA vaccine technology
BeiGene China
Amphista Therapeutics’ $53m series B
Takeda Pharmaceutical Company's Phase III SOLSTICE trial of maribavir in transplant recipients with CMV infection
Evox Therapeutics
BenevolentAI and AstraZeneca for AI and machine learning to discover potential new treatments for chronic kidney disease and idiopathic pulmonary fibrosis
MMS Holdings
ICON
Roche and Regeneron for the development, manufacture and commercialization of REGN-COV2 for COVID-19
Accord Healthcare and International Health Partners
CluePoints, BioNTech and Pfizer’s Phase I/II/III study of SARS-COV-2 RNA vaccine BNT162b2 (Comirnaty)
Moderna’s Phase III COVE study of mRNA-1273 for COVID-19 prevention
AstraZeneca’s Vaxzevria COVID-19 Vaccine
BioNTech and Pfizer’s Comirnaty (BNT162b2)
Johnson & Johnson’s single-dose COVID-19 Vaccine
Moderna’s COVID-19 Vaccine (mRNA1273)
Jingwu Zang, founder, chairman and director of I-Mab
John V Oyler, co-founder, chairman and chief executive officer of BeiGene
ADC Therapeutics
GlaxoSmithKline’s Blenrep (belantamab mafodotin) for multiple myeloma
Moderna
Dame Kate Bingham and Clive Dix